
Scientists just found a major flaw in a key COVID drug study
The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid this effort, researchers quickly homed in on part of SARS-Cov-2’s molecular structure known as the NiRAN domain — an enzyme region essential to viral replication that’s common to many coronaviruses. A drug targeting the NiRAN domain would likely…